↓ Skip to main content

Dove Medical Press

Article Metrics

A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis

Overview of attention for article published in Journal of Pain Research, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
5 tweeters
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
30 Mendeley
Title
A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis
Published in
Journal of Pain Research, April 2018
DOI 10.2147/jpr.s164128
Pubmed ID
Authors

Yuji Uchio, Hiroyuki Enomoto, Levent Alev, Yuki Kato, Hiroyuki Ishihara, Toshinaga Tsuji, Toshimitsu Ochiai, Shinichi Konno

Abstract

To examine the efficacy and safety of duloxetine in Japanese patients with knee pain due to osteoarthritis. Patients were randomized to receive duloxetine 60 mg/day or placebo for 14 weeks in a double-blind manner (ClinicalTrials.gov Identifier: NCT02248480). The primary efficacy endpoint was mean change in Brief Pain Inventory pain severity (BPI-Severity) average pain. Secondary endpoints included improvement in other BPI-Severity scales, Patient Global Impression of Improvement, Clinical Global Impressions of Severity, health-related quality of life (HRQoL) scales, range of motion of the knee joint, safety and tolerability, and structural changes on X-ray images. Of the 354 randomized patients, 161 in the duloxetine group and 162 in the placebo group completed the study. BPI-Severity average pain improved significantly with duloxetine vs. placebo (-2.57 vs. -1.80; adjusted mean difference: -0.77; 95% CI: -1.11 to -0.43; P<0.0001). Secondary efficacy endpoints and most HRQoL scales showed greater improvements in the duloxetine group than the placebo group. Adverse events observed in ≥5% of patients that were more frequent in the duloxetine than placebo group were somnolence, constipation, dry mouth, nausea, malaise, and decreased appetite. There were no marked changes in range of motion of the knee joint (efficacy), X-ray images, or Kellgren-Lawrence grade (safety) in either group. Duloxetine reduced pain and improved function in patients with knee osteoarthritis, without causing X-ray abnormalities or altered knee joint mobility. Reduced pain was associated with improved HRQoL. Adverse events were consistent with duloxetine's known safety profile.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 13%
Other 3 10%
Student > Ph. D. Student 3 10%
Student > Doctoral Student 2 7%
Student > Postgraduate 2 7%
Other 8 27%
Unknown 8 27%
Readers by discipline Count As %
Medicine and Dentistry 8 27%
Nursing and Health Professions 4 13%
Pharmacology, Toxicology and Pharmaceutical Science 3 10%
Sports and Recreations 2 7%
Philosophy 1 3%
Other 4 13%
Unknown 8 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2019.
All research outputs
#3,671,897
of 15,314,536 outputs
Outputs from Journal of Pain Research
#315
of 1,171 outputs
Outputs of similar age
#81,887
of 280,063 outputs
Outputs of similar age from Journal of Pain Research
#15
of 35 outputs
Altmetric has tracked 15,314,536 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,171 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,063 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.